Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3592885 | 0.98 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL84833 | 0.88 | KDM4E (0.65) | RAB9ANPC1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL73742 | 0.85 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2CYP2C9CYP2C19 | |
| Succinic Acid SCHEMBL27996326 | 0.84 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL20716003 | 0.84 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL2491605 | 0.84 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL4695528 | 0.83 | KDM4E (0.51) | RAB9ANPC1SMN1; SMN2MAPTGAA | |
| SCHEMBL7892444 | 0.82 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL2278841 | 0.82 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL20715992 | 0.81 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115109011-B | Benzothiazole compound, preparation method and application | 河北师范大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| EP-1910348-B1 | BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921546-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8557810-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| WO-1999003849-A1 | FLUORESCENT DIBENZAZOLE DERIVATIVES AND METHODS RELATED THERETO | PROMEGA BIOSCIENCES, INC. (US) | 1999-01-28 | — | — | WO | disclosed |
| EP-0431943-B1 | Spiro(pyran)piperidine derivatives | MERCK & CO INC (US) | 1998-07-15 | — | — | EP | disclosed |
| US-5633247-A | ANTIARRTHYMIA AGENT | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| EP-0646112-A4 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS. | ABBOTT LAB (US) | 1997-04-02 | — | — | EP | disclosed |
| EP-0646112-A1 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-04-05 | — | — | EP | disclosed |
| WO-1993012754-A2 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1993-07-08 | — | — | WO | disclosed |
| US-5206240-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0431943-A2 | Nitrogen-containing spirocycles | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| EP-0153230-B1 | PYRIMIDO(2,1-B)BENZOTHIAZOLE DERIVATIVES AND THEIR SALTS, PROCESS AND PREPARATION INTERMEDIATES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1989-07-19 | — | — | EP | disclosed |
| EP-0153230-A2 | Pyrimido(2,1-b)benzothiazole derivatives and their salts, process and preparation intermediates, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1985-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | RAB9A 2687/4885NPC1 1112/4885SMN1; SMN2 1354/4885 |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | RAB9A 2687/4885NPC1 1112/4885SMN1; SMN2 1354/4885 |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | RAB9A 2687/4885NPC1 1112/4885SMN1; SMN2 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.